HCM
CRL icon

Highbridge Capital Management’s Charles River Laboratories CRL Stock Holding History

Highbridge Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,000
Closed -$211K – 1568
2015
Q2 		$211K Buy
+3,000
New +$222K ﹤0.01% 1272

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Highbridge Capital Management's CRL Position: Q1 2017 in Review

Highbridge Capital Management sold out of Charles River Laboratories (CRL) in Q1 2017, closing a stake of 123,713 shares — an estimated $9.43M sold.

Highbridge Capital Management first reported a position in CRL in Q3 2013 and held it in 5 quarters. The position peaked at $10.7M in Q3 2015. 300 funds tracked by Wall St. Rank hold CRL as of Q1 2017.

  • Highbridge Capital Management reported no remaining Charles River Laboratories position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 123,713 Charles River Laboratories shares in Q1 2017, an estimated $9.43M.
  • Highbridge Capital Management first reported a position in Charles River Laboratories in Q3 2013 and held it in 5 quarters.
  • Highbridge Capital Management's Charles River Laboratories position peaked at $10.7M in Q3 2015.
  • 300 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.